Intravenous iloprost for treatment of critical limb ischemia in patients unsuitable for revascularization

Basit Öğe Kaydı
dc.authoridAdademir, Taylan/0000-0003-1643-3751
dc.authorwosidCevirme, Deniz/V-9568-2017
dc.authorwosidBozkurt, Ahmet Kürşat/AAD-1464-2021
dc.authorwosidAdademir, Taylan/AAU-5783-2020
dc.contributor.authorCevirme, Deniz
dc.contributor.authorAksoy, Eray
dc.contributor.authorGul, Yasar Gokhan
dc.contributor.authorErdem, Hasan
dc.contributor.authorAdademir, Taylan
dc.contributor.authorKoksal, Cengiz
dc.contributor.authorBozkurt, Kursat
dc.date.accessioned2024-07-18T20:49:02Z
dc.date.available2024-07-18T20:49:02Z
dc.date.issued2015
dc.departmentİstanbul Bilgi Üniversitesien_US
dc.description.abstractIntroduction: Whether medical therapy alone may reduce the amputation rates in patients with chronic limb ischemia and who are unsuitable for revascularization is a controversial topic. In this study, we aimed to investigate the effects of 1 week infusion of iloprost in the treatment of patients with chronic limb ischemia. Materials and methods: Twenty-seven consecutive patients were included in the study. There were 23 men (85.2%) and 4 women (14.8%) with a mean age of 68.93 +/- 14.84 years. Patients were considered eligible if they were unsuitable for surgical and endovascular revascularization. Follow-up was made on 10th day and 6th month and included ankle brachial index and clinical assessment. Results: Minor side effects occurred in four patients (16.0%), but the treatment was continued. In-hospital mortality occurred in one patient (4.0%). Another two patients died and four patients received amputation until follow-up (overall mortality 11.1%). There was significant increase in mean ankle-brachial index values between 1st day and 10th day (p < 0.001), between 1st day and 6th month (p < 0.001), and between 10th day and 6th month (p < 0.001). Conclusion: One-week treatment with iloprost may provide both long lasting symptomatic benefit and may improve hemodynamic parameters, which were shown to predict future amputation.en_US
dc.identifier.doi10.1177/1708538114552839
dc.identifier.endpage489en_US
dc.identifier.issn1708-5381
dc.identifier.issn1708-539X
dc.identifier.issue5en_US
dc.identifier.pmid25315792en_US
dc.identifier.scopus2-s2.0-84942310197en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage483en_US
dc.identifier.urihttps://doi.org/10.1177/1708538114552839
dc.identifier.urihttps://hdl.handle.net/11411/8032
dc.identifier.volume23en_US
dc.identifier.wosWOS:000361850400006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofVascularen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCritical Limb İschemiaen_US
dc.subjectİloprosten_US
dc.subjectPeripheral Artery Diseaseen_US
dc.subjectProstacyclinen_US
dc.subjectDiseaseen_US
dc.subjectAnalogen_US
dc.titleIntravenous iloprost for treatment of critical limb ischemia in patients unsuitable for revascularizationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Web of Science Indexed Publications
PubMed Indexed Publications
Scopus Indexed Publications